Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
囊泡 肿瘤
/
PI3K/Akt/mTOR
外泌体 肿瘤生长增殖和凋亡
/ mTOR / Temsirolimus

替西罗莫司 /Temsirolimus {[allProObj[0].p_purity_real_show]}

货号：A642622 同义名： 西罗莫司脂化物 / CCI-779;Torisel

Temsirolimus是一种mTOR抑制剂，IC50为1.76 μM，激活自噬并在动物模型中防止心功能恶化。

Temsirolimus 化学结构 CAS号：162635-04-3
Temsirolimus 化学结构
CAS号：162635-04-3
Temsirolimus 3D分子结构
CAS号：162635-04-3
Temsirolimus 化学结构 CAS号：162635-04-3
Temsirolimus 3D分子结构 CAS号：162635-04-3
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Temsirolimus 纯度/质量文件 产品仅供科研

货号：A642622 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 mTOR ↓ mTORC1 ↓ mTORC2 ↓ 其他靶点 纯度
AZD-8055 ++++

mTOR (truncated), IC50: 0.13 nM

mTOR (full length), IC50: 0.8 nM

 		99%+
Gedatolisib ++++

mTOR, IC50: 1.6 nM

 		98%
GSK1059615 ++

mTOR, IC50: 12 nM

 		98%
Vistusertib +++

mTOR, IC50: 2.8 nM

 		99%+
Torin 1 +++

mTOR, IC50: 4.32 nM

 		+++

mTORC1, IC50: 2 nM

 		++

mTORC2, IC50: 10 nM

 		DNA-PK 99%+
Dactolisib +++

mTOR (p70S6K), IC50: 6 nM

 		98+%
PI-103 +

mTOR, IC50: 30 nM

 		99%+
WAY-600 ++

mTOR, IC50: 9 nM

 		99%
Voxtalisib +

mTOR, IC50: 157 nM

 		99%+
PF-04691502 ++

mTOR, Ki: 16 nM

 		98+%
Onatasertib ++

mTOR, IC50: 16 nM

 		DNA-PK 99%+
Chrysophanol ✔ EGFR 98%
Samotolisib ✔ DNA-PK 99%+
Torkinib +++

mTOR, IC50: 8 nM

 		PDGFR,DNA-PK 99%+
Everolimus 99%+
WYE-354 +++

mTOR, IC50: 5 nM

 		98%
Tacrolimus ✔ 98%
PP121 ++

mTOR, IC50: 13 nM

 		PDGFR,VEGFR 99%+
Torin 2 ++++

mTOR, IC50: 0.25 nM

 		DNA-PK 99%+
Rapamycin ++++

mTOR, IC50: ~0.1 nM

 		98%
GDC-0349 +++

mTOR, Ki: 3.8 nM

 		98%
XL388 ++

mTOR, IC50: 9.9 nM

 		+++

mTORC1, IC50: 8 nM

 		+

mTORC2, IC50: 166 nM

 		99%+
WYE-687 +++

mTOR, IC50: 7 nM

 		98+%
Apitolisib +

mTOR, Ki app: 17 nM

 		98%+
WYE-132 ++++

mTOR, IC50: 0.19 nM

 		99%+
Sapanisertib ++++

mTOR, Ki: 1.4 nM

 		99%+
BGT226 maleate ✔ 99%+
ETP-46464 ++++

mTOR, IC50: 0.6 nM

 		DNA-PK 98%
PI3K-IN-1 +

mTOR, IC50: 157 nM

 		98+%
Zotarolimus +++

FKBP-12, IC50: 2.8 nM

 		99+%
OSI-027 +++

mTOR, IC50: 4 nM

 		+

mTORC1, IC50: 22 nM

 		+

mTORC2, IC50: 65 nM

 		99%+
Ridaforolimus ++++

mTOR, IC50: 0.2 nM

 		99%+
Temsirolimus +

mTOR, IC50: 1.76 μM

 		95%
CZ415 ++

mTOR, pIC50: 8.07

 		99%+
SF2523 +

mTOR, IC50: 280 nM

 		DNA-PK 99%+
KU-0063794 ++

mTORC1, IC50: ~10 nM

 		++

mTORC2, IC50: ~10 nM

 		99%+
Omipalisib ++++

mTORC1, Ki: 0.18 nM

 		++++

mTORC2, Ki: 0.3 nM

 		99%+
Palomid 529 ✔ 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Temsirolimus 生物活性

靶点

  • mTOR

    mTOR, IC50:1.76 μM
描述 mTOR is a serine-threonine kinase that interacts with several proteins to form two distinct complexes, mTORC1 and mTORC2, which show different sensitivities to rapamycin[3]. Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus treatment at nanomolar concentrations (10 nM to <5 μM) displays a modest and selective antiproliferative activity via FKBP12-dependent mechanism but can completely inhibit the proliferation of a broad panel of tumor cells at low micromolar concentrations (5-15 μM), involving FKBP12-independent suppression of mTOR signaling. Temsirolimus treatment at micromolar but not nanomolar concentrations (20 μM) causes a marked decline in global protein synthesis and disassembly of polyribosomes, accompanied by rapid increase in the phosphorylation of translation elongation factor eEF2 and the translation initiation factor eIF2A[7]. Temsirolimus inhibits the phosphorylation of ribosomal protein S6, more potently in PTEN-positive DU145 cells than in PTEN-negative PC-3 cells, and inhibits cell growth and clonogenic survival of both cells in a concentration-dependent manner[2]. Administration of Temsirolimus (20 mg/kg i.p. 5 days/week) significantly delays the growth of DAOY xenografts by 160% after 1 week and 240% after 2 weeks, compared with controls. Single high-dose of Temsirolimus (100 mg/kg i.p) treatment induces 37% regression of tumor volume within 1 week. Temsirolimus treatment for 2 weeks also delays the growth of rapamycin-resistant U251 xenografts by 148%[5]. In a phase 2 study, 25 mg temsirolimus was intravenously (IV) conducted once per week and the VEGF-A monoclonal antibody bevacizumab 10 mg/kg IV once every 2 weeks in 58 patients with differentiated PNETs and progressive disease by RECIST, results showed response rate (RR) was 41% (23 of 56 patients). PFS at 6 months was 79% (44 of 56). Median PFS was 13.2 months (95%CI,11.2to16.6).Median overall survival was 34 months (95% CI, 27.1 to not reached). For evaluable patients, the most common grade 3 to 4 adverse events attributed to therapy were hypertension (21%), fatigue (16%), lymphopenia (14%), and hyperglycemia (14%), suggesting substantial activity and reasonable tolerability of this drug[6].

Temsirolimus 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
human 697 cell Growth inhibition assay Inhibition of human 697 cell growth in a cell viability assay, IC50=1.7 nM SANGER
human A2780 cell Growth inhibition assay Inhibition of human A2780 cell growth in a cell viability assay, IC50=5.88 nM SANGER
human A3-KAW cell Growth inhibition assay Inhibition of human A3-KAW cell growth in a cell viability assay, IC50=10.43 nM SANGER
human ACN cell Growth inhibition assay Inhibition of human ACN cell growth in a cell viability assay, IC50=13.02 nM SANGER

Temsirolimus 动物研究

Dose Mice: 2 mg/kg, 10 mg/kg[3] (i.v.); 0.6 mg/kg[4] (i.p.), 5 mg/kg - 50 mg/kg[2] (i.p.)
Administration i.v., i.p.

Temsirolimus 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03629847 Neuroendocrine Tumors Phase 1 Phase 2 Recruiting December 2018 Saudi Arabia ... 展开 >> Oncology Centre, King Faisal Specialist Hospital & Research Center Recruiting Riyadh, Saudi Arabia, 11211 Contact: Ali Aljubran, MD    966-1-4647272 ext 32084    ajubran@kfshrc.edu.sa    Contact: Lani Cabangon, RN    966-1-4647272 ext 32089    lcabangon06@kfshrc.edu.sa    Sub-Investigator: Hussein Raef          Sub-Investigator: Nora Alkahtani, MD          Sub-Investigator: Shouki Bazarbashi, MD          Sub-Investigator: Ahmed Alzahrani, MD          Sub-Investigator: Mohamed Alsubayel, MD          Sub-Investigator: Monther Kabbani, MD          Sub-Investigator: Hamad Albahli, MD          Sub-Investigator: Hadeel Almana, MD 收起 <<
NCT01184326 Solid Tumor K... 展开 >>idney Cancer 收起 << Phase 1 Completed - United States, Massachusetts ... 展开 >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT01184326 - Completed - -

Temsirolimus 参考文献

[1]2018:5896786. doi: 10.1155/2018/5896786.

[2]Wu L. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 2005 Apr 1;65(7):2825-31. doi: 10.1158/0008-5472.CAN-04-3137.

[3]Agostini D. New Insights into the Role of Exercise in Inhibiting mTOR Signaling in Triple-Negative Breast Cancer. Oxid Med Cell Longev. 2018 Sep 30;2018:5896786. doi: 10.1155/2018/5896786.

[4]33(14):1551-6. doi: 10.1200/JCO.2014.56.2082. Epub 2014 Dec 8.

[5]Geoerger B. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 2001 Feb 15;61(4):1527-32.

Temsirolimus 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.97mL

0.19mL

0.10mL

4.85mL

0.97mL

0.49mL

9.71mL

1.94mL

0.97mL

Temsirolimus 技术信息

CAS号162635-04-3
分子式C56H87NO16
分子量 1030.287
别名 西罗莫司脂化物 ;CCI-779;Torisel;US brand name: Torisel.;Torisel®
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Store in freezer, under -20°C
溶解度

DMSO: 105 mg/mL(101.91 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

无水乙醇: 200 mg/mL(194.12 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇
动物实验配方

2% DMSO+30% PEG 300 +2% Tween 80+water 7 mg/mL

Tags: Temsirolimus | 162635-04-3 | CCI-779 | CCI779 | CCI 779 | mTOR Inhibitor | PI3K/Akt/mTOR | Autophagy | Apoptosis | Anti-infection | mTOR | Autophagy | Apoptosis | Bacterial | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Temsirolimus 纯度/质量文件 | Temsirolimus 亚型比较 | Temsirolimus 生物活性 | Temsirolimus 细胞研究 | Temsirolimus 动物研究 | Temsirolimus 临床数据 | Temsirolimus 参考文献 | Temsirolimus 实验方案 | Temsirolimus 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z